• KOL
    • Hepatocellular Carcinoma
    • Jian‐qiang Cai
    • Jian‐Qiang Cai: Influence Statistics

      Jian‐Qiang Cai

      Jian‐Qiang Cai

      Show email address

      Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Jian‐Qiang Cai:Expert Impact

      Concepts for whichJian‐Qiang Caihas direct influence:Hepatocellular carcinoma,Simultaneous resection,Colorectal cancer,Colorectal liver metastases,Liver metastases,Neoadjuvant chemotherapy,Early recurrence,Local excision.

      Jian‐Qiang Cai:KOL impact

      Concepts related to the work of other authors for whichfor which Jian‐Qiang Cai has influence:Hepatocellular carcinoma,Liver cancer,Hcc patients,Transarterial chemoembolization,Surgical resection,Microvascular invasion,Lymph node metastasis.

      KOL Resume for Jian‐Qiang Cai

      Year
      2022

      Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ;

      Cancer Hospital Chinese Academy of Medical Sciences

      2021

      Department of Hepatobiliary Surgery, National Clinical Research Center for Cancer Hospital, Beijing, China

      2020

      Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021 China

      2019

      Department of Hepatobiliary Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

      Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China;

      2018

      Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, PR China. Electronic address:

      National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China;

      Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing, China

      2017

      Department of Hepatobiliary Surgery, Cancer Hospital, CAMS, Beijing 100021, P.R.China

      Cancer Institute, Chinese Academy of Medical Sciences, Beijing, China.

      2016

      Department of Abdominal Surgical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

      Cancer Institute and Hospital CAMS, Chinese Academy of Medical Sciences, beijing, China;

      2015

      Department of Abdominal Surgical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), NO.17, Panjiayuan Nanli, Beijing, 100021, P. R. China

      2014

      Hong Mu, Fang Liu, Yu-Lin Sun, Xiao-Hang Zhao, State Key Laboratory of Molecular Oncology, Cancer Institute Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

      Department of Abdominal Surgical Oncology, Cancer Hospital, Beijing, People’s Republic of China

      Email:

      2013

      Department of Abdominal Surgery, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China;

      2012

      Department of Abdominal Surgical Oncology, Cancer Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China

      2011

      Department of abdominal surgical oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P.R. China

      2010

      Authors' Affiliations: State Key Laboratory of Molecular Oncology and Department of Etiology & Carcinogenesis and Department of Abdominal Surgery, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

      2008

      Department of Abdominal Surgery, CIH, CAMS & PUMC.

      2004

      Department of Surgical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing 100021, China.

      2003

      Cancer Institue & Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China.

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Jian‐Qiang Cai is among the top experts in the world.
      Concept World rank
      psm2 shortterm outcomes #1
      nomogram early recurrence #1
      biomarkers fluorescence intensities #1
      poor css 95 #1
      early recurrence nomogram #1
      531 rnet patients #1
      prognosis crlm patients #1
      952 egc patients #1
      87 young patients #1
      patients crs score #1
      elderly crlm patients #1
      mm rectal #1
      shortterm outcomes psm2 #1
      tissue alphafetoprotein status #1
      comparable survival benefit #1
      crlm simultaneous #1
      revealed desirable #1
      css nonmetastatic patients #1
      ≥9233 tissue #1
      tissue afp status #1
      local excision 95 #1
      144 crlm patients #1
      curves hosmer #1
      fetoprotein status #1
      level ≥9233 #1
      eightyfour individual samples #1
      p0001 afppositive status #1
      ≥9233 afp #1
      p0017 pfs #1
      nln count css #1
      asialoglycoprotein receptor gpc3 #1
      afp prognosis #1
      ≥9233 #1
      independent factors serum #1
      ≥9233 afppositive status #1
      chinese 而晚期肝细胞癌缺乏有效的治疗措施 #1
      nac hepatectomy #1
      p0017 grade #1
      afppositive status #1
      cutoff nln #1
      primary colorectal sarcoma #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Jian‐Qiang Cai

      KOL-Index: 22412

      BACKGROUND: There is no standard of care for adjuvant therapy for patients with hepatocellular carcinoma. This trial was designed to assess the efficacy and safety of sorafenib versus placebo as adjuvant therapy in patients with hepatocellular carcinoma after surgical resection or local ablation.

      METHODS: We undertook this phase 3, double-blind, placebo-controlled study of patients with hepatocellular carcinoma with a complete radiological response after surgical resection (n=900) or ...

      Known for Hepatocellular Carcinoma | Sorafenib Placebo | Local Ablation | Surgical Resection | Adjuvant Therapy
      KOL-Index: 14126

      BACKGROUND AND AIMS: Golgi protein 73 (GP73) as a potential serum marker for hepatocellular carcinoma (HCC) has not been validated in large cohort studies. Furthermore, its significance in the assessment of tumour recurrence after HCC resection remains unknown. The aim of this study was to determine the value of serum GP73 in the diagnosis of HCC.

      METHODS: Serum GP73 and alpha-fetoprotein (AFP) were compared in a total of 4217 human subjects in this multicentre study, including 1690 ...

      Known for Patients Hcc | Golgi Protein | Serum Gp73 | Tumor Carcinoma | Specificity Afp
      KOL-Index: 13025

      BackgroundGastrectomy was reported to be an excessive approach for early gastric cancer with signet ring cell carcinoma. This study was conducted to explore the feasibility of endoscopic submucosal dissection for early gastric with signet ring cell carcinoma.MethodsData from 1067 patients who underwent gastrectomy for early gastric cancer were collected retrospectively. The association between the clinicopathological factors and the lymph node metastasis was analyzed by univariate and ...

      Known for Lymph Node Metastasis | Early Gastric Cancer | Ring Cell | Tumor Size | Carcinoma Signet
      KOL-Index: 11059

      APOBEC3s are a family of cytidine deaminases involved in innate cellular immunity against virus including hepatitis B virus (HBV). A germline deletion across APOBEC3A and APOBEC3B (A3B) genes results in complete removal of the A3B coding region and destroys A3B expression. To determine whether this deletion affects susceptibility to HBV infection and HBV-related hepatocellular carcinoma (HCC), A3B genotypes were analyzed in 1124 individuals with HCC, 510 individuals with persistent HBV ...

      Known for Hepatocellular Carcinoma | Hbv Infection | Gene Deletion | Hepatitis Virus | Hcc Cells
      KOL-Index: 10489

      Hepatocellular carcinoma (HCC) is one of the most common diseases worldwide, with extremely poor prognosis due to failure in diagnosing it early. Alpha-fetoprotein (AFP) is the only available biomarker for HCC diagnosis; however, its use in the early detection of HCC is limited, especially because about one-third of patients afflicted with HCC have normal levels of serum AFP. Thus, identifying additional biomarkers that may be used in combination with AFP to improve early detection of ...

      Known for Afp Hcc | Early Detection | Human Hepatocellular | Tissue Transglutaminase | Liver Cancer
      KOL-Index: 9865

      The receptor-interacting protein kinase 1 (RIPK1) is an essential signaling molecule in pathways for cell survival, apoptosis, and necroptosis. We report here that RIPK1 is upregulated in human colorectal cancer and promotes cell proliferation when overexpressed in a colon cancer cell line. RIPK1 interacts with mitochondrial Ca2+ uniporter (MCU) to promote proliferation by increasing mitochondrial Ca2+ uptake and energy metabolism. The ubiquitination site of RIPK1 (RIPK1-K377) was ...

      Known for Mitochondrial Ca2 | Cell Proliferation | Colorectal Cancer | Inbred Balb Mice | Energy Metabolism
      KOL-Index: 9766

      Purpose: The prognosis for patients with refractory soft-tissue sarcoma (STS) is dismal. Anlotinib has previously shown antitumor activity on STS in preclinical and phase I studies.Patients and Methods: Patients 18 years and older, progressing after anthracycline-based chemotherapy, naïve from angiogenesis inhibitors, with at least one measurable lesion according to RECIST 1.1, were enrolled. The main subtypes eligible were undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), ...

      Known for Soft Tissue | Anlotinib Patients | Antitumor Activity | Angiogenesis Inhibitors | Synovial Sarcoma
      KOL-Index: 9698

      BACKGROUND: Recent genome-wide association studies have identified 10 single nucleotide polymorphisms (SNP) associated with colorectal cancer (CRC) in Caucasians. This study evaluated the effects of these newly identified SNPs in a Chinese population.

      METHODS: We assessed the associations of these 10 SNPs with CRC in a case-control study that consisted of 2,124 cases and 2,124 controls. Odds ratios (OR) and 95% confidence intervals were computed by logistic regression, and cumulative ...

      Known for Chinese Population | Colorectal Cancer | Risk Crc | Genome Wide | Genetic Variants
      KOL-Index: 9675

      Assessing the prognosis of patients with hepatocellular carcinoma (HCC) by the number and size of tumors is sometimes difficult. The main purpose of the study was to evaluate the prognostic value of total tumor volume (TTV), which combines the two factors, in patients with HCC who underwent liver resection. We retrospectively reviewed 521 HCC patients from January 2001 to December 2008 in our center. Patients were categorized using the tertiles of TTV. The prognostic value of TTV was ...

      Known for Hepatocellular Carcinoma | Liver Resection | Total Tumor Volume | Patients Hcc | Prognostic Ttv
      KOL-Index: 9479

      Tumor-initiating cell (TIC) is a subpopulation of cells in tumors that are responsible for tumor initiation and progression. Recent studies indicate that hepatocellular carcinoma-initiating cells (HCICs) confer the high malignancy, recurrence and multi-drug resistance in hepatocellular carcinoma (HCC). In this study, we found that Icaritin, a prenylflavonoid derivative from Epimedium Genus, inhibited malignant growth of HCICs. Icaritin decreased the proportion of EpCAM-positive (a HCICs ...

      Known for Hepatocellular Carcinoma | Malignant Growth | Janus Kinase | Hcc Icaritin | Tumor Cells
      KOL-Index: 9396

      Background: Hepatocellular carcinoma (HCC) (about 85-90% of primary liver cancer) is particularly prevalent in China because of the high prevalence of chronic hepatitis B infection. HCC is the fourth most common malignancy and the third leading cause of tumor-related deaths in China. It poses a significant threat to the life and health of Chinese people.

      Summary: This guideline presents official recommendations of the National Health and Family Planning Commission of the People's ...

      Known for Primary Liver Cancer | Hcc China | Hepatocellular Carcinoma | Staging Treatment | Expert Opinions
      KOL-Index: 9067

      To date, the useful markers of hepatocellular carcinoma (HCC) remains incompletely developed. Here, we show that annexin A2 complement alpha-fetoprotein (AFP), a widely used liver cancer marker, in the serologically surveillance and early detection of HCC. First, differentially expressed proteins in HCC were identified using a subcellular proteomic approach. Annexin A2 was then selected for further verification. It was found to be overexpressed in HCC tissues (60.7%, 136/224). Using a ...

      Known for Tumor Carcinoma | Early Hepatocellular | Hcc Annexin | Liver Cancer | Female Hepatitis
      KOL-Index: 8835

      Hepatocellular carcinoma (HCC) is one of the most common digestive system malignant tumors. Due to the resistance to radiotherapy, the prognosis in patients with HCC is poor. Based on previous studies and online tools prediction, we hypothesized that miR-92b, which was reported to promote HCC cell proliferation, might bind to p57kip2, a well-known tumor suppressor, to modulate the radioresistance of HCC to ionizing radiation (IR) -based radiotherapy. In the present study, a higher ...

      Known for Hepatocellular Carcinoma | Ionizing Radiation | P57kip2 Expression | Hcc Cells | Kinase Inhibitor
      KOL-Index: 8665

      BACKGROUND: Lymph node status is crucial to determining treatment for early gastric cancer (EGC). We aim to establish a nomogram to predict the possibility of lymph node metastasis (LNM) in EGC patients.

      METHODS: Medical records of 952 EGC patients with curative resection, from 2002 to 2014, were retrospectively retrieved. Univariate and multivariate analysis were performed to examine risk factors associated with LNM. A nomogram for predicting LNM was established and internally ...

      Known for Lymph Node Metastasis | Lnm Nomogram | Early Gastric | Egc Patients | Tumor Size

      Key People For Hepatocellular Carcinoma

      Top KOLs in the world
      #1
      Jordi Bruix
      hepatocellular carcinoma liver transplantation patients hcc
      #2
      Josep María Llovet
      hepatocellular carcinoma advisory consultancy liver transplantation
      #3
      Vincenzo Mazzaferro
      hepatocellular carcinoma liver transplantation patients hcc
      #4
      Freddie Ian Bray
      cancer incidence nordic countries mortality rates
      #5
      Jacques Ferlay
      cancer incidence global burden latin america
      #6
      Hashem B EL‐SERAG
      united states hepatocellular carcinoma veterans affairs

      Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ; | Cancer Hospital Chinese Academy of Med

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.